References
- National diabetes statistics report. Centers for Disease Control and Prevention, 2014. Available at: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf [Last accessed 27 June 2014]
- Obesity and overweight. World Health Organization, 2014. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/ [Last accessed 27 June 2014]
- Garber AJ. Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs 2012;21:45-57
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
- A1c distribution among adults with diagnosed diabetes, United States, 1988–1994 to 1999–2006. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/statistics/a1c/A1c_dist.htm [Last accessed 7 February 2013]
- Aronoff SL, Berkowitz K, Shreiner B, et al. Glucose metabolism and regulation: beyond insulin and glucagon. Diabet Spectrum 2004;3:183-90
- Schwartz S. Evidence-based practice use of incretin-based therapy in the natural history of diabetes. Postgrad Med 2014;126:66-84
- Hauber AB, Han S, Yang J-C, et al. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence 2013;7:937-49
- Hauber AB, Johnson FR, Sauriol L, et al. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care 2005;28:2243-5
- Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Health 2011;14:403-13
- Kruger DF, LaRue S, Estepa P. Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes 2015;8:49-56
- Train K. Discrete choice methods with simulation. Cambridge: CUP, 2003
- Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of Simulation Methods in Environmental and Resource Economics. Dordrecht (Netherlands): Springer, 2005:117-34
- Hechmati G, Hauber AB, Arellano J, et al. Patients’ preferences for bone metastases treatments in France, Germany and the United Kingdom. Supportive Care Cancer 2015;23:21-8
- Arellano J, Hauber AB, Mohamed AF, et al. Physicians’ preferences for bone metastases drug therapy in the United States. Value Health 2015;18:78-83
- Bae JP, Dobesh PP, Klepser DG, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18:139-46
- García-Pérez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4:175-94
- Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-34
- Fu A, Qui Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin 2009;25:1413-20
- Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther 2014;31:1119-33
- Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes. J Med Econ 2010;13:655-61
- Shingler SL, Swinburn P, Ali S, et al. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis. J Med Econ 2013;16:1036-42
- Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009;26:722-8